AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28209175
Drug: Pressure garment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure garment therapy only
Trial: 31565952
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical silicone gel and pressure garment therapy
Trial: 24806033
Drug: TVR 2250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVR 2250 mg
Trial: 24806033
Drug: TVR 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVR 1500 mg
Trial: 23257888
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.5% levobupivacaine injected at T10, T11, and T12 paravertebral spaces
Trial: 23257888
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.9% NaCl solution
Trial: 16572610
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg (oral preoperative dose)
Trial: 16572610
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg (2 IM doses before surgery and after 12 hours)
Trial: 6310241
Drug: 1,25(OH)2D3 (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 (mean dose 0.5 micrograms daily)
Trial: 6310241
Drug: D3 (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 (dose 100 micrograms daily)
Trial: 29893182
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) delivered in group sessions once a week for eight weeks
Trial: 29893182
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with citalopram (30-50 mg/day at therapeutic dosages)
Trial: 22463125
Drug: 12-week intensive
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week intensive intervention of nutrition and exercise education, coping skills training and exercise (Phase I), followed by 9 months of continued monthly contact (Phase II) and then 6 months follow-up on their own.
Trial: 20135645
Drug: Aspirin, Statins,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, Statins, Other NSAIDs
Trial: 18084988
Drug: Modified fascia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified fascia iliaca compartment block with 30 ml 0.5% bupivacaine with 1:200,000 adrenaline, 150 microg clonidine and 9 ml 0.9% saline
Trial: 18084988
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 40 ml 0.9% saline
Trial: 16046714
Drug: FOS/fiber formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOS/fiber formula (5.1 g/L FOS and 8.9 g/L fiber)
Trial: 12404081
Drug: Caffeine (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (65 mg) consumed in de-caffeinated coffee at 1000, 1100, 1200, and 1300 hours
Trial: 12404081
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg) consumed at 1300 hours
Trial: 11783152
Drug: Puerarin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin with conventional treatment
Trial: 7848120
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (control group after treatment)
Trial: 1983346
Drug: high-dose H2-blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose H2-blockade with ranitidine 300 mg q.d.s.
Trial: 1983346
Drug: high-dose H2-blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose H2-blockade with ranitidine 1200 mg o.m.
Trial: 1983346
Drug: high-dose H2-blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose H2-blockade with sufotidine 600 mg b.d.
Trial: 23049928
Drug: Weekly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly text message support intervention
Trial: 20948256
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with S‐1 (more than 50% of the total scheduled dose)
Trial: 20948256
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with S‐1 (less than 50% of the total scheduled dose)
Trial: 17635756
Drug: Intensive multiple
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multiple risk factor modification (targeting hypercholesterolaemia, hyperhomocysteinaemia, anaemia and disordered bone mineral metabolism)
Trial: 7547855
Drug: Liquid fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid fibre (LF) 300 ml
Trial: 2127790
Drug: Recombinant alpha‐interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha‐interferon (5 mega units thrice weekly for 2 months, then 1.5 mega units until the eighteenth month)
Trial: 25852206
Drug: EPA+DHA (3.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA (3.9 g/day)
Trial: 23298459
Drug: Instructional sets
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Instructional sets emphasizing concussion history or gender (specifics on dosage and duration not available)
Trial: 23298459
Drug: Gender stereotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender stereotype condition (specifics on dosage and duration not available)
Trial: 15172862
Drug: Intrauterine lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine lidocaine (3 mL of buffered 2% lidocaine solution)
Trial: 9578059
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autologous stem cell support
Trial: 9928572
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose treatment
Trial: 7830545
Drug: Degni‐Cordeiro's microsurgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degni‐Cordeiro's microsurgical indirect lymphatico‐venous shunt (L.V.S.) surgery
Trial: 29284183
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral food challenge (OFC)
Trial: 28933961
Drug: 17β-Estradiol (E2),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17β-Estradiol (E2), 0.72 mg transdermally for 2-8 weeks
Trial: 28933961
Drug: 17β-Estradiol (E2),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17β-Estradiol (E2), 0.62 mg and norethindrone acetate (P), 2.70 mg for 3-16 weeks
Trial: 28933961
Drug: Estra-1,3,5(10)-triene-3,16α, 17β-triol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estra-1,3,5(10)-triene-3,16α, 17β-triol (E3) vaginal tablet 0.5 mg per month five times
Trial: 21592309
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (30 mg)
Trial: 18440921
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone (15 mg)
Trial: 16529577
Drug: Testogel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testogel (5 g containing 50 mg testosterone, daily) for 4 weeks, followed by tadalafil (20 mg, twice a week)
Trial: 16529577
Drug: Testogel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testogel (5 g containing 50 mg testosterone, daily) for 10 weeks before adjunctive therapy with tadalafil
Trial: 16529577
Drug: Testogel and
RxNorm normalized name: Testopel
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testogel and tadalafil combination therapy
Trial: 9236443
Drug: Dual-chamber rate-responsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-chamber rate-responsive pacemaker therapy
Trial: 7958108
Drug: ELISA for
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA for insulin antibodies (IA) in IDDM patients
Trial: 7958108
Drug: ELISA for
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA for insulin antibodies (IA) in NIDDM patients treated with insulin
Trial: 7958108
Drug: ELISA for
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Trial: 7958108
Drug: ELISA for
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA for insulin autoantibodies (IAA) in Graves' disease patients
Trial: 7958108
Drug: RBA for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Trial: 7958108
Drug: RBA for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBA for insulin autoantibodies (IAA) in Graves' disease patients
Trial: 3309444
Drug: 3% Acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Acyclovir eye ointment
Trial: 3309444
Drug: 3% Adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Adenosine Arabinoside eye ointment
Trial: 23276775
Drug: Guided intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided intervention (10 session workbook, 10 biweekly, 8 monthly, and 6 bimonthly phone coaching calls, bimonthly weight graphs, tailored letters)
Trial: 19956091
Drug: Hemin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemin (3 mg/kg intravenously in 25% albumin)
Trial: 19083412
Drug: Iron-fortified fermented
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified fermented milk beverage supplemented with Lactobacillus acidophilus (3 mg iron per 80 mL)
Trial: 12939317
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate (0.6 mol/L)
Trial: 7747212
Drug: Low social
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low social class, age 45-64 years, poor social network, not feeling secure in daily life, not taking regular exercise
Trial: 3746
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D preparation
Trial: 28363704
Drug: Interviewer-administered version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interviewer-administered version of PM-3D4D
Trial: 28363704
Drug: Self-administered version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered version of PM-3D4D
Trial: 23691266
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg oral, 1 month before surgery)
Trial: 16983909
Drug: Integrated Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Chinese and Western medicine (ICWM) protocol
Trial: 16983909
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine plus placebo
Trial: 15545307
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg R411 as a single oral dose
Trial: 15545307
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg RO0270608 as an intravenous infusion
Trial: 15545307
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of R411 (10-1200 mg)
Trial: 15545307
Drug: Repeated oral
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated oral doses of R411 (50-900 mg) for up to 3 weeks
Trial: 8289475
Drug: ETI (Etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETI (Etoposide 80 mg/m2, Thioguanine 100 mg/m2 twice a day on days 1-5, Idarubicin 15 mg/m2 on days 1-3)
Trial: 8289475
Drug: TAD (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAD (Oral Thioguanine 100 mg/m2 twice a day on days 1-5, i.v. Cytarabine, Daunorubicin 60 mg/m2 on day 5)
Trial: 3301058
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of streptokinase
Trial: 3301058
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in the coronary care unit
Trial: 24897083
Drug: Oritavancin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oritavancin (1200 mg single intravenous dose)
Trial: 24897083
Drug: Vancomycin (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (twice daily for 7 to 10 days)
Trial: 18349181
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron disintegrating tablets (ODT)
Trial: 11320369
Drug: Eprosartan (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (400 to 800 mg daily)
Trial: 10322821
Drug: Kangaibao oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaibao oral liquid (KABOL)
Trial: 8494577
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 20 mg
Trial: 8494577
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 40 mg
Trial: 8494577
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 80 mg
Trial: 8494577
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 120 mg
Trial: 8494577
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 180 mg
Trial: 8494577
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 240 mg
Trial: 8494577
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 360 mg
Trial: 3115081
Drug: Oligosaccharides infusion
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligosaccharides infusion (144 +/- 41.0 g/day)
Trial: 3115081
Drug: Oligosaccharides infusion
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligosaccharides infusion
Trial: 27846922
Drug: Brexpiprazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (2 mg, 4 mg) in short-term fixed-dose studies
Trial: 27846922
Drug: Brexpiprazole (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (2-4 mg) in flexible-dose short-term study
Trial: 27846922
Drug: Brexpiprazole in
RxNorm normalized name: Product containing brexpiprazole in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole in maintenance study (1-4 mg)
Trial: 25829142
Drug: Raloxifene (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (120 mg daily)
Trial: 20005355
Drug: Everolimus-based immunosuppression
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus-based immunosuppression regimen with discontinuation of cyclosporine or tacrolimus (group 2)
Trial: 9153737
Drug: N-9 vaginal
RxNorm normalized name: (+/-)-N-methylephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-9 vaginal gel (Advantage-24), 52.5 mg, applied once daily for 2 weeks
Trial: 9153737
Drug: Placebo gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel, applied once daily for 2 weeks
Trial: 8423760
Drug: Prophylactic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic ibuprofen (400 mg TID initiated 4 h before exercise)
Trial: 8423760
Drug: Therapeutic ibuprofen
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic ibuprofen (400 mg TID initiated 24 h after baseline)
Trial: 15567009
Drug: Prophylactic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic ibuprofen
Trial: 8423760
Drug: Prophylactic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic and therapeutic ibuprofen
Trial: 31595954
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (LDCT) with prior AAD
Trial: 22329591
Drug: Amlodipine 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5-5 mg plus amiloride/hydrochlorothiazide 1.25-2.5 mg/12.5-25 mg (Group A)
Trial: 22329591
Drug: Amlodipine 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5-5 mg plus telmisartan 40-80 mg (Group T)
Trial: 18457470
Drug: Agomelatine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 50 mg
Trial: 18457470
Drug: Agomelatine 25
RxNorm normalized name: Agomelatine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 25 mg
Trial: 12196749
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream dosed twice daily
Trial: 12196749
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream dosed once daily
Trial: 12196749
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream dosed 5 times a week
Trial: 12196749
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream dosed 3 times a week
Trial: 7760888
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 mg per day for 48 hours)
Trial: 2328197
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg 12 hourly
Trial: 2328197
Drug: Lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 400 mg 12 hourly
Trial: 85937
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid 250 mg/day combined with propranolol 80 mg twice daily
Trial: 23657005
Drug: Transglucosidase (TGD)
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transglucosidase (TGD) 300 or 900 mg/day for 12 weeks
Trial: 21851461
Drug: Serotonergic antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic antidepressant
Trial: 17239888
Drug: Atorvastatin/Niacin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin/Niacin ER
Trial: 2546778
Drug: Chemotherapy (etoposide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (etoposide, doxorubicin, methotrexate (VAM) and procarbacine, vincristine, cyclophosphamide, lomustine (POCC) with prophylactic cranial irradiation (30 Gy))
Trial: 2546778
Drug: Sequential hemibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential hemibody irradiation (SHBI)
Trial: 612628
Drug: Tinidazole, 50
RxNorm normalized name: Tinidazole, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole, 50 mg/kg once
Trial: 612628
Drug: Metronidazole, 50
RxNorm normalized name: MetroNIDAZOLE, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole, 50 mg/kg once
Trial: 31747959
Drug: abPI‐VSD (antibiotic-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abPI‐VSD (antibiotic-containing drainage fluid)
Trial: 31747959
Drug: Antibiotic irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic irrigation solution without abPI‐VSD
Trial: 20597110
Drug: Abatacept 10
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A)
Trial: 17600622
Drug: Modafinil treatment
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil treatment for 2 weeks
Trial: 17600622
Drug: Pre-treatment scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment scan
Trial: 15764868
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean achieved dose 106 +/- 38 mg/d)
Trial: 10606310
Drug: Golytely 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golytely 20 ml/kg (up to 1 L) per hour for 4 h with clear liquid diet for 1 day (group C)
Trial: 8606813
Drug: Digoxin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.5 mg/daily)